Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28420679 | 0.82 | FFAR3 (0.31) | — | |
| SCHEMBL18789280 | 0.82 | NPSR1 (0.35) | NPSR1MAPTLMNA | |
| SCHEMBL18849596 | 0.82 | NPSR1 (0.35) | NPSR1MAPTLMNA | |
| SCHEMBL1469083 | 0.80 | — | — | |
| SCHEMBL23888104 | 0.79 | NPSR1 (0.32) | NPSR1MAPT | |
| SCHEMBL19363923 | 0.79 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL17784063 | 0.78 | FFAR3 (0.36) | NPSR1MAPTLMNA | |
| SCHEMBL2775123 | 0.76 | NPSR1 (0.50) | NPSR1MAPTLMNA | |
| SCHEMBL25228494 | 0.76 | NPSR1 (0.45) | NPSR1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL30657499 | 0.74 | NPSR1 (0.31) | NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417386-A1 | INHIBITORS OF RET | MIDCAP FINANCIAL TRUST | 2024-12-19 | — | — | US | disclosed |
| CN-118056823-A | Preparation of key intermediate of platinib | 江苏慧聚药业股份有限公司 | 2024-05-21 | — | — | CN | disclosed |
| EP-4331585-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4292594-A2 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3371171-B1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-111423416-B | Inhibitors of RET | 缆图药品公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| EP-4126877-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20190185454-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2019-06-20 | — | — | US | disclosed |
| EP-3371171-A1 | INHIBITORS OF RET | Blueprint Medicines Corporation (US) | 2018-09-12 | — | — | EP | disclosed |
| US-10030005-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030005-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030005-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2017079140-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017079140-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121312-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121312-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121312-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417386-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885MAPT 1447/4885LMNA 3350/4885 |
| US-20170121312-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885MAPT 1447/4885LMNA 3350/4885 |
| US-20190185454-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885MAPT 1447/4885LMNA 3350/4885 |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINA3, SERPINC1 | NPSR1 3542/4885MAPT 2268/4885LMNA 2300/4885 |
| US-10030005-B2 | Inhibitors of RET | RET, HRAS, RB1 | NPSR1 3593/4885MAPT 1447/4885LMNA 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.